Robert Langreth on Muck Rack

Robert Langreth

Verified
  • Science and Health Reporter-at-Large, Bloomberg News
  • None, Bloomberg
New York
As seen in: Bloomberg News, UOL Economia, MSN, MSN Ireland, UOL, Bloomberg Businessweek, Bloomberg Green Daily, Bloomberg Markets Magazine, Cinco Días, ET Healthworld, Forbes and
Science and health reporter at large, Bloomberg News
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Robert

Contact Robert, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Congressional Panel Probes Drugmakers’ Trials in China (1) Original

|
By Robert Langreth Verified
| Bloomberg Law Verified
A US congressional committee is probing drugmakers’ clinical trials in China, including sites linked to the country’s military or conducted in areas where Beijing has been accused of targeting minorities.
Open in Who Shared View Duplicates (2) Issue with article?

美國國會委員會對製藥商在中國開展臨床試驗展開調查

|
By Robert Langreth Verified
| Yahoo! Finance Hong Kong Verified
【彭博】-- 美國一個國會委員會正在調查製藥商在中國開展的臨床試驗，包括在與中國軍方有關聯的地點進行的試驗，或在中國被指責不公平對待少數族裔的地區開展的試驗。 根據彭博新聞社看到的分別致禮來、默克、輝瑞、艾伯維和百時美施貴寶等五大製藥商的信函，美國眾議院中國問題特別委員會要求這些公司在7月中旬前提供詳細信息，內容涉及在中國軍方醫療中心以及新疆地區開展的試驗。 默克在一份聲明中表示，「患者安全和倫理誠信是」其試驗項目的「根本優先事項」，並表示該公司認同「所有臨床試驗都應在維護人權的同時，按照同樣高的倫理標準開展，無論地點在哪裡」。 禮來一名發言人表示，該公司已收到委員會的信函，正在仔細評估。艾伯維拒絕置評。其他兩家製藥公司沒有立即回覆尋求置評的電子郵件。 美國大型製藥公司越來越依賴從中國獲得許可的藥物來充實其研發管線。但交易越來越多引起了華盛頓的警覺，使其擔憂這可能會對製藥行業構成競爭威脅，或可能帶來安全風險。6月份，五角大樓將中國一家大型製藥商列入與中國軍方有關聯的公司名單，此舉可能會使美國企業與該公司進行合作變得更加困難。 路透和Endpoints...
Open in Who Shared Issue with article?

Amgen Drug Tavneos’ Main Study Retracted by Medical Journal (1) Original

|
By Ike Swetlitz Verified, Robert Langreth Verified
| Bloomberg Law Verified
A clinical trial used to approve ’s pill Tavneos was retracted Monday from the , putting the drug’s continued sales at risk. Two of the study’s authors requested the retraction, the journal said Monday. The journal cited a US Food and Drug Administration investigation that found the results of nine patients were changed after the study’s database was finalized and some researchers were unblinded, meaning they were told which patients got the experimental drug and which did not.
Open in Who Shared View Duplicates (2) Issue with article?
See all 2,924 licensed articles (4,171 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified